Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: Its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease

Parkinsonism and Related Disorders

Volumn 8, Issue 4, 2002, Pages 247-253

  Youdim, M B H ^a   Tipton, K F ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

2 Phenylethylamine; l Deprenyl; Monoamine oxidase B; Parkinson's disease; Rasagiline

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; DOPAMINE; PHENETHYLAMINE; RASAGILINE; SELEGILINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; ENZYME ACTIVITY; ENZYME INHIBITION; HALF LIFE TIME; LIVER; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; STEREOTYPY;

ANIMALS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; INDANS; MALE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE, SECONDARY; PHENETHYLAMINES; PSYCHOTROPIC DRUGS; RATS; RATS, SPRAGUE-DAWLEY; SELEGILINE; STEREOTYPED BEHAVIOR;

EID: 0036162584     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(01)00011-6     Document Type: Article

References (57)

1. Selegiline in de novo Parkinson patients: The French multicentre trial (FMST)
2. Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms?
3. Rescue of axotomized immature rat facial motorneurons by R (-)-deprenyl: Stereospecificity and independence from monoamine oxidase inhibition
4. 11C]-deprenyl
5. In vivo release of endogenous dopamine, 5-hydroxytryptamine and some other metabolites from rat cauadate nucleus by phenylehtylamine
6. Effects of p-chloro-beta-phenylethylamine on the uptake and release of putative amine neurotransmitters in rat brain
7. Implications of combined treatment with 'Mardopar' and L-deprenyl in Parkinson's disease. A long term therapy
8. Increased life expectancy resulting from addition of L-deprenyl to Mardopar treatment in Parkinson's disease: A long-term study
9. The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation
10. The novel neuropsychotropic agent milacemide is a specific enzyme-activated inhibitor of brain monoamine oxidase B
11. The turnover of the A- and B-forms of monoamine oxidase in rat liver
12. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; Effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopaminergic neurons
13. 14C]-pargyline: A tool for studying the synthesis of the enzyme
14. Pharmacology of rasagiline (N-propargyl-1R-aminoindan)
15. Slow recovery of human brain MAO B after L-deprenyl (Selegiline) withdrawal
16. Is selegiline neuroprotective in Parkinson's disease?
17. Effect of monoamine oxidase inhibition by clorgyline, deprenyl or tranylcypromine on 5-hydroxytryptamine concentration in rat brain and hyperactivity following subsequent tryptophan administration
18. Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition necessary for increased functional activity of dopamine and 5-hydroxytryptamine
19. Chronic TVP-1012 (rasagiline) dose-activity response of monoamine oxidase A and B in the brains of common Marmoset
20. 3H) beta-phenylethylamine binding sites in rat brain
21. Neuroprotective effect of rasgline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse
22. Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B
23. The effect of long term treatment with monoamine oxidase A and B inhibitors on dopamine release from striatum in vivo
24. Clinical mythology - IX: Pyramid sales in the bucket shop: DATATOP bottoms out
25. Does selegiline provide a symptomatic or neuroprotective effect - Discussion
26. Protein measurement with the Folin phenol reagent
27. Relations between the degree of monoamine oxidase inhibition and some psychopharmacological responses to monoamine oxidase inhibition in rats
28. Mechanism underlying anti-apoptotic activity of a l-deprenyl-related propargylamine, rasagiline
29. Selegiline as initial treatment in de novo parkinsonian patients
30. Neuronal monoamine oxidase: Specific enzyme types and their rates of formation
31. Intra- and extra-synaptosomal deamination of dopamine and noradrenaline by the two forms of human brain monoamine oxidase. Implications for the neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in man
32. Clinical trials with rasagiline mesylate, a new drug for treatment of Parkinson's disease
33. Effect of deprenyl on the progression of disability in early Parkinson's disease
34. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
35. 2-Phenylethylamine: A modulator of catecholamine transmission in the mammalian central nervous system
36. Possible mechanism of action of deprenyl in parkinsonism
37. L-Deprenyl therapy in Thai patients with Parkinson's disease: Before and after clinical trial of 50 patients
38. In vivo release of endogenous dopamine from rat caudate nucleus
39. Monoamine oxidase activity and monoamine metabolism in brains of Parkinsonian patients treated with l-deprenyl
40. Location of MAO-A and MAO-B in human brain: Step in understanding the therapeutic action of l-deprenyl
41. Deprenyl reduces death of motorneurons caused by axotomy
42. Selective inhibition of monoamine oxidase B by propargyl-containing drugs
43. DATATOP and clinical mythology IX (plus replies from others)
44. (R)(+)-N-propargyl-1-aminoindan rasagiline and derivatives: Highly selective and potent inhibitors of monoamine oxidase B
45. The oxidation of tryptamine by the two forms of monoamine oxidase in human tissues
46. Amphetamine metabolites of deprenyl involved in protection against neurotoxicity induced by MPTP and 2′-methyl MPTP
47. Rescue of dying neurons: A new of action deprenyl in MPTP parkinsonism
48. (-)-Deprenyl reduces PC 12 cell apoptosis by inducing new protein synthesis
49. The effect of deprenyl on the natural history of Parkinson's disease
50. Monoamine oxidase inhibitors as antidepressants
51. The assay of monoamine oxidase activity
52. Distinct MAO-A and B populations in primate brain
53. Monoamine oxidase
54. R-Enantiomers of N-propargyl-aminoindan compounds. Their preparations and pharmacological compositions containing them
55. Neuroprotective properties of the antiparkinson drug, rasagiline and its optical isomer
56. Rasagline, N-propargyl-R-(+)-1-aminoindan, a potent selective irreversible inhibitor of monoamine oxidase
57. The antiparkinson drug, rasagiline and its derivatives exert neuroprotection unrelated to MAO inhibition incell culture and in vivo